AR128377A1 - Anticuerpo contra btla y sus usos - Google Patents

Anticuerpo contra btla y sus usos

Info

Publication number
AR128377A1
AR128377A1 ARP230100205A ARP230100205A AR128377A1 AR 128377 A1 AR128377 A1 AR 128377A1 AR P230100205 A ARP230100205 A AR P230100205A AR P230100205 A ARP230100205 A AR P230100205A AR 128377 A1 AR128377 A1 AR 128377A1
Authority
AR
Argentina
Prior art keywords
seq
lcvr
hcvr
sequence
monoclonal antibody
Prior art date
Application number
ARP230100205A
Other languages
English (en)
Spanish (es)
Inventor
Juying Li
Qian Zhang
Bingqing Shen
Francisco Adrian
Liang Schweizer
Original Assignee
Hifibio Hk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Hk Ltd filed Critical Hifibio Hk Ltd
Publication of AR128377A1 publication Critical patent/AR128377A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ARP230100205A 2022-01-29 2023-01-30 Anticuerpo contra btla y sus usos AR128377A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2022075109 2022-01-29

Publications (1)

Publication Number Publication Date
AR128377A1 true AR128377A1 (es) 2024-04-24

Family

ID=87470720

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230100205A AR128377A1 (es) 2022-01-29 2023-01-30 Anticuerpo contra btla y sus usos

Country Status (12)

Country Link
US (1) US20250388673A1 (https=)
EP (1) EP4469482A4 (https=)
JP (1) JP2025504543A (https=)
KR (1) KR20240139083A (https=)
CN (1) CN118871465A (https=)
AR (1) AR128377A1 (https=)
AU (1) AU2023212896A1 (https=)
CA (1) CA3250219A1 (https=)
IL (1) IL314579A (https=)
MX (1) MX2024009309A (https=)
TW (1) TW202340253A (https=)
WO (1) WO2023143564A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2097447A4 (en) * 2006-11-15 2010-12-29 Medarex Inc HUMAN MONOCLONAL ANTIBODIES AGAINST BTLA AND METHODS OF USE
BR112012007875A2 (pt) * 2009-07-31 2016-11-22 Medarex Inc anticorpos totalmente humanos para btla
MX2018010295A (es) * 2016-02-26 2019-06-06 Inst Nat Sante Rech Med Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
CN110790837A (zh) * 2018-08-02 2020-02-14 上海君实生物医药科技股份有限公司 抗btla抗体

Also Published As

Publication number Publication date
AU2023212896A1 (en) 2024-08-22
WO2023143564A1 (en) 2023-08-03
EP4469482A4 (en) 2026-05-06
TW202340253A (zh) 2023-10-16
US20250388673A1 (en) 2025-12-25
IL314579A (en) 2024-09-01
JP2025504543A (ja) 2025-02-12
MX2024009309A (es) 2024-08-27
CA3250219A1 (en) 2023-08-03
EP4469482A1 (en) 2024-12-04
KR20240139083A (ko) 2024-09-20
CN118871465A (zh) 2024-10-29

Similar Documents

Publication Publication Date Title
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP3763387B1 (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
US20210070849A1 (en) Use of anti-family with sequence similarity 19, member a5 antibodies for the treatment of neuropathic pain
CL2021001235A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
RU2017137010A (ru) Анти-сеасам6 антитела и их применения
RU2769569C2 (ru) Нейтрализация ингибиторных путей в лимфоцитах
RU2019111722A (ru) Антитела против siglec-15 и способы их применения
AR093046A2 (es) Un anticuerpo humanizado que se une al cd20 humano, o un fragmento del mismo, una composicion, un articulo de fabricacion, uso de dichos anticuerpos para la fabricacion de un medicamento para tratar cancer, enfermedades autoinmunes y artritis reumatoidea, un vector de expresion y una celula huesped
FI3250592T3 (fi) Transtyretiinin vastaisia vasta-aineita
WO2021203030A3 (en) Methods of use of anti-trem2 antibodies
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2025002112A (es) Composiciones de proteina de fusion recombinante neuregulina-1 (nrg-1) humana y metodos para su uso
CO6341480A2 (es) Anticuerpos recombinantes contra el factor de crecimiento del endotelio vascular (vegf)
CN103097414A (zh) 膜联蛋白1抗体
MX2022006147A (es) Metodos de tratamiento del cancer utilizando anticuerpos anti-ox40 en combinacion con anticuerpos anti-pd1 o anti-pdl1.
AR126112A1 (es) Moléculas de unión a gpc3
CN117980329A (zh) 用于预防或治疗自身免疫疾病的抗体药品
PE20220287A1 (es) Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
AR128377A1 (es) Anticuerpo contra btla y sus usos
MX2022006148A (es) Metodos para tratamiento del cancer usando anticuerpos anti-ox40 en combinacion con anticuerpos anti-tigit.
RU2020115161A (ru) Днк моноклональных антител против ctla-4 для лечения и профилактики рака
PE20250390A1 (es) Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
MX2022004058A (es) Kir3dl3 es un receptor inhibidor del sistema inmunitario y usos del mismo.
AR134568A1 (es) Anticuerpos